Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality

NCT ID: NCT00684034

Last Updated: 2014-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

131 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The influence of hemodialysis on oxidative stress, endothelial activation, inflammation and on the redox state of lymphocytes should be clarified as well as the putative relationships between all these parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to now, no anti-oxydative treatment has been able to reduce the mortality of the patients with Kidney Failure. Thus it is necessary to have a better knowledge of oxydative stress mechanisms in patients with KF in order to find more efficacious treatments. The influence of hemodialysis upon oxidative stress is not well known.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Renal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Volunteer healthy

Group Type OTHER

Sampling of blood

Intervention Type OTHER

A sampling of blood will be made

2

Patient dialysis patient

Group Type OTHER

Sampling of blood

Intervention Type OTHER

A sampling of bood will be made before the dialysis

3

Not dialysed chronic renal insufficient patient

Group Type OTHER

Sampling of blood

Intervention Type OTHER

A sampling of blood will be made.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sampling of blood

A sampling of blood will be made

Intervention Type OTHER

Sampling of blood

A sampling of bood will be made before the dialysis

Intervention Type OTHER

Sampling of blood

A sampling of blood will be made.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 and 80 years old man or woman dialysing at least 3 times a week for at least 6 months and having no residual renal function
* Rate of haemoglobin \> 11 g / dl
* Clinically stable patient that is having had no considerable event (cardiovascular problem, infection, surgical operation) with the exception of angioplasty of fistula or prosthesis vascular, in the previous 3 months the entrance to the study
* Patient capable of understanding and of following the essay, in particular knowing how to read the note of information.

Exclusion Criteria

* Pregnant woman
* Treatment by corticoids or immunosuppresseurs
* hemopathy sly
* chronic cancer or infection in evolution
* Cardiovascular event (infarct, unstable angor, coronary bypasses, confusions of the rhythm, AVC, amputation) or infectious (blood-poisoning, pneumopathie, meningitis) or surgical operation in the previous 3 months the inclusion in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bertrand DUSSOL, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique des Hopitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital de la Conception- Service de Néphrologie et de transplantation rénale

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-38

Identifier Type: -

Identifier Source: secondary_id

2007-A01179-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Red Blood Cell Lifespan
NCT01462071 TERMINATED